PTPRC and sarcoma: We then injected intratumorally Ad-PIB-eGFP or a control Ad vector (Ad-Stuffer-eGFP) into two human xenograft models (A2058 melanoma and SKLMS1 sarcoma) and detected transduction (eGFP+ 5.0 ± 2.7% SKLMS1; 0.3 ± 0.2% A2058), in situ reprogramming (CD45+HLA-DR+ 3.9 ± 0.7% SKLMS1; 16.6 ± 2.5% A2058) and increased HLA-ABC expression (Fig. 6H and fig.